Long-Term Survival and Risk of Liver Cancer After Direct-Acting Antiviral Treatment in HCV-Infected Patients Depending on the Degree of Liver Fibrosis
Background/Objectives: Despite the high effectiveness of direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection, patients remain at risk of liver malignancy and premature mortality. We evaluated long-term liver malignancy incidence and survival according to baseline fibrosis stage. Methods: This retrospective, single-center study included 1399 DAA treatment records (2015–2025). After excluding 22 early deaths and 15 earlier treatment records from patients undergoing retreatment, 1362 patients were included in long-term analyses, beginning 12 weeks after DAA completion, irrespective of sustained virological response status. Of 24 patients with pre-existing HCC, 16 remained in the long-term cohort. Incident liver malignancies excluded recurrence or progression of pre-existing HCC. Time-to-event outcomes were assessed using Kaplan–Meier and Cox proportional hazards methods. Results: During a median follow-up of 6.3 years, 33 liver malignancies occurred among 298 patients with cirrhosis (1343.6 person-years), compared with five cases among 1064 patients without cirrhosis (5705.5 person-years). Incidence rates were 2.46 and 0.09 cases per 100 person-years, respectively (incidence rate ratio [IRR] = 28; (95% CI: 10–92). Cirrhosis was strongly associated with liver malignancy development (hazard ratio [HR] = 19.1; 95% CI: 7.2–51.1). Five-year overall survival was 95.7% (95% CI: 94–97%) in patients with F0–F2 fibrosis, 86.4% (78.7–91.5%) in those with F3 fibrosis, and 65.7% (59.3–71.4%) in patients with cirrhosis (F4). Conclusions: Liver malignancy risk persists following DAA treatment, particularly among patients with cirrhosis. Although the absolute incidence was low among patients without cirrhosis, cirrhosis was associated with substantially higher liver malignancy incidence and reduced long-term survival.
Authors
- Krystyna Dobrowolska (ORCID: https://orcid.org/0000-0003-0352-9893)
- Michał Brzdęk (ORCID: https://orcid.org/0000-0002-1180-9230)
- Piotr Rzymski (ORCID: https://orcid.org/0000-0002-4713-0801)
- Robert Flisiak (ORCID: https://orcid.org/0000-0003-3394-1635)
- Dorota Zarębska‐Michaluk (ORCID: https://orcid.org/0000-0003-0938-1084)
- Kinga Brzdęk (ORCID: https://orcid.org/0009-0009-2339-8684)
- Jakub Janczura (ORCID: https://orcid.org/0009-0004-7977-9797)
- Klaudia Fedorek-Foltyn
Institutions
- Poznan University of Medical Sciences (PL)
- Medical University of Białystok (PL)
- Jan Kochanowski University (PL)
- Copernicus Memorial Hospital (PL)
- Medical University of Lodz (PL)
Publication Details
- Journal
- Cancers
- Published
- 2026-11-17
- DOI
- https://doi.org/10.3390/cancers18223665
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 0.00